Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear

CooperVision, Inc.88 enrolled

Overview

The aim of the study is to evaluate if the performance of Invigor A is substantially equivalent to Invigor B contact lenses when used in a one month recommended replacement, daily wear modality.

This study is a multi-centered, daily wear, monthly replacement, bilateral, randomized in a ratio of two to one (2:1) Test to Control, lens blocked (subjects remain in the same lens brand throughout the study), licensed investigator and subject masked, concurrent controlled study with a study duration of approximately three months evaluating performance equivalence of Invigor A (test) over Invigor B (control) contact lenses.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Myopia Hyperopia Astigmatism

Interventions

Invigor A (test)DEVICE

silicone hydrogel lens

Invigor B (control)DEVICE

silicone hydrogel lens

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Inclusion Criteria: 1. Be at least 18 years of age as of the date of evaluation for the study 2. Have 1. Read the informed consent document 2. Been given an explanation of the informed consent document 3. indicated understanding of the informed consent document 4. Signed the informed consent document 3. Be willing and able to adhere to the instructions provided by the investigational site and be willing to keep all specified appointments. 4. Be an adapted, frequent replacement, current full - time silicone hydrogel or soft contact lens wearer. An adapted full- time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study. 5. Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses. 6. Be in good general health, based on his/her knowledge. * Exclusion Criteria: 1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. Note: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis. 2. Poor personal hygiene. 3. Any active participation in another clinical trial during this trial or within 30 days prior to this study. 4. To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months. 5. A member, relative or household member of the investigator(s) or of the investigational office staff. 6. A known sensitivity to the ingredients used in the multi-purpose solution approved for use in the study and is unable or unwilling to use the alternate care system. 7. Had previous refractive surgery; or current or previous orthokeratology treatment. 8. Aphakic or pseudophakic. 9. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes. 10. The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day. 11. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections. 12. A history of papillary conjunctivitis that has interfered with contact lens wear.

Locations (6)

Mark Nakano. O.D

Torrance, California, United States

Vision Care Associates

East Lansing, Michigan, United States

The Koetting Associates

St Louis, Missouri, United States

Quinn, Foster & Associates

Athens, Ohio, United States

Outcomes

Primary Outcomes

Number of Eyes With Epithelial Edema - Slit Lamp Findings

Epithelial edema on slit lamp grading scale 0 - 4 (0- No microcysts; normal transparency, 1 Trace - 1 to 20 microcysts; barely discernible local epithelial haziness, 2 Mild - 21 to 50 microcysts; faint but definite localized or generalized haziness, 3 Moderate - 51 to 100 microcysts; significant localized or generalized haziness, 4 Severe - \>100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea, or numerous coalescing bullae)

Time frame: Baseline

Number of Eyes With Epithelial Edema - Slit Lamp Findings

Time frame: One Month

Number of Eyes With Stromal Edema - Slit Lamp Findings

Stromal edema on slit lamp grading scale 0-4 (0 None - No edema, 1 Trace - Just detectable clouding, 2 Mild - faint corneal striae, 3 Moderate - Pronounced corneal striae, 4 severe - folds in Descemet's membrane and ≥4 pronounced striae

Time frame: Baseline

Number of Eyes With Stromal Edema - Slit Lamp Findings

Time frame: One Month

Number of Eyes With Corneal Vascularization - Slit Lamp Findings

Corneal Vascularization on slit lamp grading scale 0-4 (0 None: No vessel penetration, 1 Trace: \<1.00 mm vessel penetration, 2 Mild: \>1.00 mm to \<1.50 mm vessel penetration, 3 Moderate: \>1.50 mm to \<2.00 mm vessel penetration, 4 Severe: Vessel penetration \>2.00 mm) Depth: a. - Epithelial b. - Anterior Stromal c. - Mid/Posterior Stromal Location: N - Nasal T - Temporal I - Inferior S - Superior

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.